In this systematic review and meta-analysis of twelve studies, including 1147 patients, we assessed the frequency of NAEs in advanced or metastatic ALK/ROS1-positive NSCLC patients treated with lorlatinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.